News

Prostate cancer: Early enzalutamide substantially improves time to progression and overall survival when added to standard mHSPC therapy (testosterone suppression ± docetaxel)

An interim analysis of the international randomised, phase 3 ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer (mHSPC) who received the non-steroidal anti-androgen (NSAA) medicine enzalutamide along with the standard-of-care treatment were alive after 3 years...

Ibudilast affects brain atrophy in PPMS, not SPMS

In the randomised phase 2 trial SPRINT-MS, the effect of ibudilast on brain measures of integrity was evaluated in both primary and secondary progressive MS (PPMS and SPMS). Results of a post-hoc analysis suggested that the effect of ibudilast on...